Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?

J Clin Oncol. 2006 Dec 10;24(35):5618-9. doi: 10.1200/JCO.2006.07.6398.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Breast Neoplasms / complications
  • Breast Neoplasms / drug therapy*
  • Chemotherapy, Adjuvant
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Drug Administration Schedule
  • Epirubicin / administration & dosage
  • Epirubicin / adverse effects
  • Female
  • Fever / prevention & control
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Humans
  • Leukocytosis / chemically induced
  • Leukocytosis / prevention & control*
  • Neutropenia / chemically induced
  • Neutropenia / prevention & control*
  • Recombinant Proteins

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Epirubicin
  • Cyclophosphamide
  • Filgrastim